172 related articles for article (PubMed ID: 29567476)
1. Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma.
Li W; Zhang G; Li X; Wang X; Li Q; Hong L; Shen Y; Zhao C; Gong X; Chen Y; Zhou J
Biochem Biophys Res Commun; 2018 May; 499(3):416-424. PubMed ID: 29567476
[TBL] [Abstract][Full Text] [Related]
2. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
[TBL] [Abstract][Full Text] [Related]
3. TRIP13 promotes lung cancer cell growth and metastasis through AKT/mTORC1/c-Myc signaling.
Cai W; Ni W; Jin Y; Li Y
Cancer Biomark; 2021; 30(2):237-248. PubMed ID: 33136091
[TBL] [Abstract][Full Text] [Related]
4. TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma.
Tao Y; Yang G; Yang H; Song D; Hu L; Xie B; Wang H; Gao L; Gao M; Xu H; Xu Z; Wu X; Zhang Y; Zhu W; Zhan F; Shi J
Oncotarget; 2017 Apr; 8(16):26718-26731. PubMed ID: 28157697
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of thyroid hormone receptor interactor 13 is associated with human hepatocellular carcinoma.
Ju L; Li X; Shao J; Lu R; Wang Y; Bian Z
Oncol Rep; 2018 Dec; 40(6):3794-3802. PubMed ID: 30542731
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of TRIP13 promotes the malignant progression of lung cancer via the EMT pathway.
Lu R; Zhou Q; Ju L; Chen L; Wang F; Shao J
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184074
[TBL] [Abstract][Full Text] [Related]
7. TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis.
Zhang G; Zhu Q; Fu G; Hou J; Hu X; Cao J; Peng W; Wang X; Chen F; Cui H
Br J Cancer; 2019 Dec; 121(12):1069-1078. PubMed ID: 31740732
[TBL] [Abstract][Full Text] [Related]
8. TRIP13 promotes the proliferation and invasion of lung cancer cells via the Wnt signaling pathway and epithelial-mesenchymal transition.
Li ZH; Lei L; Fei LR; Huang WJ; Zheng YW; Yang MQ; Wang Z; Liu CC; Xu HT
J Mol Histol; 2021 Feb; 52(1):11-20. PubMed ID: 33128167
[TBL] [Abstract][Full Text] [Related]
9. TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer.
Sheng N; Yan L; Wu K; You W; Gong J; Hu L; Tan G; Chen H; Wang Z
Cell Death Dis; 2018 Mar; 9(3):402. PubMed ID: 29540729
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of NMI promotes tumor growth and predicts poor prognosis in human lung adenocarcinomas.
Wang J; Zou K; Feng X; Chen M; Li C; Tang R; Xuan Y; Luo M; Chen W; Qiu H; Qin G; Li Y; Zhang C; Xiao B; Kang L; Kang T; Huang W; Yu X; Wu X; Deng W
Mol Cancer; 2017 Oct; 16(1):158. PubMed ID: 29025423
[TBL] [Abstract][Full Text] [Related]
11. Thyroid Receptor-Interacting Protein 13 is Correlated with Progression and Poor Prognosis in Bladder Cancer.
Niu L; Gao Z; Cui Y; Yang X; Li H
Med Sci Monit; 2019 Sep; 25():6660-6668. PubMed ID: 31486418
[TBL] [Abstract][Full Text] [Related]
12. Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma.
Afaq F; Agarwal S; Bajpai P; Diffalha SA; Kim HG; Peter S; Khushman M; Chauhan SC; Mukherjee P; Varambally S; Manne U
Neoplasia; 2024 Jan; 47():100951. PubMed ID: 38039923
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway.
Gao Y; Liu S; Guo Q; Zhang S; Zhao Y; Wang H; Li T; Gong Y; Wang Y; Zhang T; Dong Z; Bacich D; Chowdhury WH; Rodriguez R; Wang Z
Int J Biol Sci; 2019; 15(7):1488-1499. PubMed ID: 31337978
[TBL] [Abstract][Full Text] [Related]
14. TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway.
Xiao Z; Li M; Zhang X; Rong X; Xu H
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36896765
[TBL] [Abstract][Full Text] [Related]
15. TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer.
Dong L; Ding H; Li Y; Xue D; Li Z; Liu Y; Zhang T; Zhou J; Wang P
Int J Biol Macromol; 2019 Jan; 121():200-206. PubMed ID: 30267820
[TBL] [Abstract][Full Text] [Related]
16. NCAPG2 promotes tumour proliferation by regulating G2/M phase and associates with poor prognosis in lung adenocarcinoma.
Zhan P; Xi GM; Zhang B; Wu Y; Liu HB; Liu YF; Xu WJ; Zhu Q; Cai F; Zhou ZJ; Miu YY; Wang XX; Jin JJ; Li Q; Lv TF; Song Y
J Cell Mol Med; 2017 Apr; 21(4):665-676. PubMed ID: 27862966
[TBL] [Abstract][Full Text] [Related]
17. [TRIP13 Enhances Radioresistance of Lung Adenocarcinoma Cells
through the Homologous Recombination Pathway].
Ge S; Gu R; Yang X; Xu C; Wang S; Zhu G
Zhongguo Fei Ai Za Zhi; 2024 Jan; 27(1):1-12. PubMed ID: 38296621
[TBL] [Abstract][Full Text] [Related]
18. TRIP13 knockdown inhibits the proliferation, migration, invasion, and promotes apoptosis by suppressing PI3K/AKT signaling pathway in U2OS cells.
Yu DC; Chen XY; Zhou HY; Yu DQ; Yu XL; Hu YC; Zhang RH; Zhang XB; Zhang K; Lin MQ; Gao XD; Guo TW
Mol Biol Rep; 2022 Apr; 49(4):3055-3064. PubMed ID: 35032258
[TBL] [Abstract][Full Text] [Related]
19. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the TRIP13 level in breast cancer and insights into potential molecular pathways.
Lan J; Huang J; Tao X; Gao Y; Zhang L; Huang W; Luo J; Liu C; Deng Y; Liu L; Liu X
J Cell Mol Med; 2022 May; 26(9):2673-2685. PubMed ID: 35322916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
